INZY Stock Plummets to 52-Week Low at $0.91 Amid Steep Decline

Inozyme Pharma Inc (INZY) stock has tumbled to a 52-week low, touching a price level of just $0.91. While InvestingPro analysis suggests the stock is currently undervalued, the company’s financial health score remains weak, with analyst price targets ranging from $7 to $23. This significant drop reflects a harrowing year for the biopharmaceutical company, with its stock price plummeting by -87.99% over the past year. Investors have watched with concern as INZY’s market position weakened, culminating in this latest low point. The company, which specializes in developing treatments for rare diseases, has faced numerous challenges that have evidently shaken investor confidence and led to a dramatic decrease in its stock valuation. Despite these challenges, the company maintains a healthy current ratio of 3.56, indicating strong short-term liquidity. (InvestingPro subscribers can access 12 additional key insights about INZY’s financial position.)

In other recent news, Inozyme Pharma Inc. has reported promising interim results from its ENERGY 1 trial and Expanded Access Program, focusing on the investigational drug INZ-701 for infants and young children with ENPP1 Deficiency. The data showed improvements in survival rates and heart function, with no serious treatment-related adverse events. Additionally, Inozyme has completed enrollment for its ENERGY 3 pivotal trial in pediatric patients, with topline data expected in early 2026. Piper Sandler recently adjusted its price target for Inozyme to $23, maintaining an Overweight rating, citing a promising outlook for INZ-701 and the company’s strategic reprioritization efforts. Meanwhile, H.C. Wainwright reaffirmed a Buy rating with a $16 price target, emphasizing INZ-701’s regulatory progress with orphan drug designations from the EMA and FDA. Raymond (NSE:RYMD) James also made adjustments, reducing its price target to $24 while maintaining an Outperform rating, noting potential concerns about anti-drug antibodies but expressing confidence in the treatment’s developments. These updates reflect Inozyme’s continued focus on addressing rare genetic disorders, with potential approvals and market launches anticipated in the coming years.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.